Valuation -- 5/10
| Company | Market Cap | Trailing P/E | Fwd P/E | FY26E EPS Gr. | Div Yield |
|---|---|---|---|---|---|
| Church & Dwight (CHD) | $22.0B | 30.8x | 24.7x | 5-8% | 1.3% |
| Procter & Gamble (PG) | ~$380B | ~21x | ~23x | -- | ~2.5% |
| Colgate-Palmolive (CL) | ~$75B | ~33x | ~28x | -- | ~2.2% |
| Clorox (CLX) | ~$19B | ~17x | ~16x | -- | ~3.4% |
| Kimberly-Clark (KMB) | ~$42B | ~18x | ~13x | -- | ~3.7% |
| Key Takeaway | CHD commands a premium to CLX and KMB on organic growth and M&A track record. CL trades higher on stronger international/EM exposure. PEG of 3.1-4.9x is expensive. Consensus target of ~$102 implies ~10% upside. | ||||
| # | Catalyst | Timeline | Magnitude | Probability |
|---|---|---|---|---|
| 1 | Touchland scaling globally | 2026-2028 | High | Medium-High |
| Highest-upside catalyst. ~$200M revenue, growing double-digits with international expansion just beginning (Canada, Middle East, 20-30 more countries in regulatory pipeline). Mgmt avoiding mass channel to protect brand equity. | ||||
| 2 | TheraBreath toothpaste launch | 1H 2026 | Medium | High |
| 12-hour bad breath claim, 4.7-star reviews, 8 clinical studies. Enters a large category and extends the franchise beyond rinse. Early rinse-to-paste conversion rates are high. | ||||
| 3 | ARM & HAMMER $2B to $3B roadmap | 2026-2029 | High | Medium |
| Multi-year story via good/better/best strategy, new adjacencies, and reclaiming licensed categories. ARM & HAMMER laundry was the only brand gaining share in Q4. Mgmt expects meaningful progress over 4 years. | ||||
| 4 | Portfolio cleanup drag falls off | Done | Medium | Realized |
| Exits of Vitamins, Flawless, Spinbrush, and Waterpik showerheads are complete. Reported sales guided down 0.5-1.5% in 2026 purely from these exits, masking 3-4% organic growth. | ||||
| 5 | Gross margin +100bps guided for FY26 | FY 2026 | Medium | Medium-High |
| Premium mix shift (Touchland, Hero, TheraBreath) and productivity programs provide further runway. Margin expansion supports multiple stability. | ||||
| 6 | International acceleration | FY 2026 | Medium | Medium |
| 8% organic growth guided for international in 2026. Hero Cosmetics expanding to 100+ countries by end 2026. | ||||
| 7 | Tariff exposure reduced from $190M to ~$25M | Ongoing | Medium | High |
| Aggressive supply chain restructuring. No longer sourcing Waterpik flossers from China. Proactive tariff mitigation reduces cost uncertainty. | ||||
| 8 | Private label exposure reduced 12% to 5% | Done | Medium | Realized |
| Vitamin business exit removed the biggest PL-exposed segment. Remaining brands hold strong #1/#2 category positions. | ||||
| # | Risk | Severity | Probability | Mitigant |
|---|---|---|---|---|
| 1 | Valuation compression | HIGH | Medium | 25x forward PE leaves limited margin of safety. De-rating already underway (-18% from highs) but could compress further on any miss. |
| 2 | Tariff re-escalation | HIGH | Medium | Initial $190M exposure showed vulnerability. Supply chain actions cut to ~$25M, but new tariff rounds could reopen risk. |
| 3 | Elevated promotional environment in HPC | MEDIUM | High | Competitors spending heavily in laundry and litter. ARM & HAMMER value positioning helps; below-category promo spend and still gaining share. |
| 4 | SAP ERP transition execution risk | MEDIUM | Low-Medium | Upgrade (not greenfield); dedicated team with high confidence. No major sell-in planned around go-live. ERP transitions carry inherent disruption risk. |
| 5 | Macro / consumer weakness | MEDIUM | Medium | CHD skews value but categories only growing ~2%. Value tier outperforming, and share gains in key categories provide a buffer. |
| 6 | Touchland channel / brand dilution | MEDIUM | Low | Mgmt explicitly avoiding mass channel. Costco test showed no Sephora/Ulta cannibalization. Risk is well-managed but not zero. |
| 7 | Private label competition (remaining categories) | MEDIUM | Medium | PL exposure down from 12% to 5% after Vitamin exit. Remaining brands have strong #1/#2 positions in their categories. |
| 8 | OxiClean Costco delisting | LOW-MED | Realized | Lost major club placement. One-time headwind being lapped in 2026; not structural. |
| 9 | FX headwinds on international | LOW | Medium | ~15% international revenue limits exposure. 8% organic growth guided for 2026 absorbs some FX drag. |
| 10 | Commodity / inflation persistence | MEDIUM | Medium | 3% inflation baked into 2026 guide. Productivity programs + mix shift to premium personal care offset, but sustained inflation would pressure margins. |
| 11 | ARM & HAMMER concentration risk | LOW-MED | Low | Brand diversification improving via Hero, TheraBreath, and Touchland acquisitions. But ARM & HAMMER remains the cornerstone. |
- Touchland becomes a $500M+ brand; international expansion drives outsized growth
- TheraBreath toothpaste launch succeeds, extending the franchise into a large category
- ARM & HAMMER makes credible progress toward $3B via adjacencies and premiumization
- Portfolio cleanup complete -- cleanest brand portfolio in company history
- Gross margin expansion continues as premium mix increases (Touchland, Hero, TheraBreath)
- Tariff exposure managed down to ~$25M removes a major cost overhang
- 3-4% organic growth disappoints at 25x forward -- multiple compresses to 20-21x
- Touchland / TheraBreath growth disappoints; acquisition integration underperforms
- Elevated promotional spending in laundry and litter erodes margins industry-wide
- SAP ERP transition disrupts operations during go-live period
- Macro deterioration weakens even value-tier consumption; categories stall below 2% growth
- Tariff re-escalation reopens cost exposure beyond the $25M managed level
Score of 5/10 reflects a balanced risk/reward profile with meaningful concerns on valuation and macro sensitivity, offset by credible catalysts from portfolio reshaping and brand momentum. The stock is not cheap enough to provide a margin of safety, and several risks could compress the multiple further.
Why not higher (6-7): At 24.7x forward earnings with 5-8% EPS growth, the PEG ratio of 3.1-4.9x is expensive for a staples compounder. Organic growth of 3-4% is good-not-great for this multiple. Categories are only growing ~2%. Promotional spending is elevated industry-wide. The SAP transition introduces execution risk. Consensus target of ~$102 implies only ~10% upside with a wide range ($74-$115) that signals uncertainty. The 1.3% dividend yield is the lowest among HPC peers.
Why not lower (3-4): CHD has never had a cleaner portfolio. The exits of low-margin, high-PL-exposure businesses (Vitamins, Flawless, Spinbrush) are done. Touchland, Hero, and TheraBreath provide genuine above-algorithm growth vectors. Gross margin guided +100bps in 2026 with further runway as premium mix increases. ARM & HAMMER value positioning is a tailwind in the current consumer environment. Tariff exposure managed down aggressively from $190M to ~$25M. The 18% de-rating from highs has pulled the stock closer to fair value.
Net assessment: At $92.85, the risk/reward is balanced but does not offer asymmetric upside. This is a HOLD / Watchlist position. The biggest swing factors are whether Touchland can become a $500M+ brand and whether ARM & HAMMER can credibly reach $3B -- both multi-year stories. Near-term, the 100bps gross margin guide and 3-4% organic growth need to be delivered cleanly to hold the multiple. A miss on either would likely send the stock to the low-$80s.